The prevailing view of fecal microbiota transplantation centers on bacterial restoration, but emerging evidence suggests immune reprogramming may be equally crucial for preventing recurrent C. difficile infections. This mechanistic insight could transform how we understand and optimize microbiome therapies for infectious diseases and potentially broader immune-mediated conditions.
Researchers analyzed immune cell changes in 37 participants receiving either lyophilized fecal microbiota transplants (LFMT) or sterile fecal filtrate controls. Single-cell RNA sequencing revealed distinct transcriptional signatures in LFMT recipients, with upregulated regulatory genes including CD69, STAT1, TOX, RORA, and FOXP3 across CD4+ and CD8+ T cells. Simultaneously, cytotoxic gene expression decreased, including GZMB, PRF1, and GNLY markers. These changes suggest enhanced immune regulation rather than inflammatory responses, indicating the transplanted microbiota actively reshapes host immune programming.
This finding challenges the bacterial replacement model of FMT success and positions immune modulation as a primary therapeutic mechanism. The specific upregulation of regulatory T cell markers aligns with murine studies showing these cells are essential for C. difficile clearance. However, the study's limitation to two participants for detailed sequencing analysis means broader validation is needed. If confirmed across larger cohorts, this immune reprogramming paradigm could guide development of targeted microbiome interventions that optimize both bacterial engraftment and therapeutic immune responses, potentially expanding FMT applications beyond infectious diseases into autoimmune and inflammatory conditions.